114 7 pRopERTy, plANT ANd EquIpmENT Total property, Land and Plant and Assets in course plant and buildings equipment of construction equipment $m $m $m $m Cost At 1 January 2006 4,490 8,035 480 13,005 Capital expenditure 23 196 577 796 Additions through business combinations 26 26 Transfer of assets into use 154 494 648 Disposals and other movements 35 300 3 338 Exchange adjustments 450 912 57 1,419 At 31 December 2006 5,082 9,363 463 14,908 Capital expenditure 53 304 812 1,169 Additions through business combinations 302 122 176 600 Transfer of assets into use 151 470 621 Disposals and other movements 23 555 16 594 Exchange adjustments 254 470 28 752 At 31 December 2007 5,819 10,174 842 16,835 Capital expenditure 49 239 825 1,113 Transfer of assets into use 275 404 679 Disposals and other movements 123 558 25 706 Exchange adjustments 803 1,725 100 2,628 At 31 December 2008 5,217 8,534 863 14,614 Depreciation At 1 January 2006 1,320 4,700 6,020 Charge for year 203 747 950 Impairment 6 47 53 Disposals and other movements 21 277 298 Exchange adjustments 148 582 730 At 31 December 2006 1,656 5,799 7,455 Charge for year 227 849 1,076 Impairment 39 65 2 106 Disposals and other movements 3 498 1 502 Exchange adjustments 96 306 402 At 31 December 2007 2,015 6,521 1 8,537 Charge for year 247 812 1,059 Impairment 91 32 123 Disposals and other movements 120 529 2 651 Exchange adjustments 303 1,192 2 1,497 At 31 December 2008 1,930 5,644 3 7,571 Net book value At 31 December 2006 3,426 3,564 463 7,453 At 31 December 2007 3,804 3,653 841 8,298 At 31 December 2008 3,287 2,890 866 7,043 Impairment charges in 2008 are attributable to the productivity initiatives in the global supply chain in France and research and development in Canada.
These costs were recognised in cost of sales and research and development in the income statement.
Impairment charges in 2007 are attributable to the productivity initiatives in the global supply chain in Germany and the write-down of business support assets.
These costs were recognised in cost of sales and general and administrative expenses in the income statement.
Impairment charges in 2006 are attributable to the write-down of assets in relation to the termination of NXY-059 and the write-down of assets in association with Toprol-XL, resulting from the introduction of generic competition in the US.
The charges were recognised in cost of sales in the income statement.
ASTRAZENECA ANNuAl REpoRT ANd FoRm 20-F INFoRmATIoN 2008
